180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases
Yahoo! Finance
PALO ALTO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has entered into a new, exclusive global licensing agreement with The University of Oxford (“Oxford”) for the development and commercialization of HMGB1, a regenerative molecule for promoting l
Continue Reading